Line-M Tablet contains Levocetirizine 5mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, reducing symptoms such as rhinorrhea, sneezing, nasal congestion, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a selective leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor in the airway, thereby preventing bronchoconstriction, inflammation, and mucus production commonly observed in asthma and allergic rhinitis. The synergistic action of these two agents offers comprehensive control of allergic symptoms by targeting multiple inflammatory pathways. Line-M Tablet is indicated for the management of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma to improve symptom control and reduce exacerbations. It is generally well tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal discomfort. Dosage and administration should be as prescribed by a healthcare professional, considering patient-specific factors. This combination therapy enhances patient compliance by simplifying treatment regimens while providing rapid and sustained symptom relief.